AU2002366989A1 - A method for assessing the potential responsiveness of a subject to anti-cancer drugs affecting the ras signal transduction pathway - Google Patents

A method for assessing the potential responsiveness of a subject to anti-cancer drugs affecting the ras signal transduction pathway

Info

Publication number
AU2002366989A1
AU2002366989A1 AU2002366989A AU2002366989A AU2002366989A1 AU 2002366989 A1 AU2002366989 A1 AU 2002366989A1 AU 2002366989 A AU2002366989 A AU 2002366989A AU 2002366989 A AU2002366989 A AU 2002366989A AU 2002366989 A1 AU2002366989 A1 AU 2002366989A1
Authority
AU
Australia
Prior art keywords
assessing
subject
signal transduction
transduction pathway
cancer drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002366989A
Inventor
Smadar Avigad
Drorit Luria
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIO GENE TECHNOLOGIES Inc
Original Assignee
BIO GENE TECHNOLOGIES Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BIO GENE TECHNOLOGIES Inc filed Critical BIO GENE TECHNOLOGIES Inc
Publication of AU2002366989A1 publication Critical patent/AU2002366989A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2002366989A 2001-12-31 2002-12-30 A method for assessing the potential responsiveness of a subject to anti-cancer drugs affecting the ras signal transduction pathway Abandoned AU2002366989A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL14742101A IL147421A0 (en) 2001-12-31 2001-12-31 A METHOD OF SCREENING FOR POTENTIAL RESPONDERS TO ANTI-CANCER DRUGS AFFCTING THE Ras SIGNALING PATHWAY
IL147421 2001-12-31
PCT/IL2002/001056 WO2003060161A2 (en) 2001-12-31 2002-12-30 A method for assessing the potential responsiveness of a subject to anti-cancer drugs affecting the ras signal transduction pathway

Publications (1)

Publication Number Publication Date
AU2002366989A1 true AU2002366989A1 (en) 2003-07-30

Family

ID=11075919

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002366989A Abandoned AU2002366989A1 (en) 2001-12-31 2002-12-30 A method for assessing the potential responsiveness of a subject to anti-cancer drugs affecting the ras signal transduction pathway

Country Status (3)

Country Link
AU (1) AU2002366989A1 (en)
IL (1) IL147421A0 (en)
WO (1) WO2003060161A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090186024A1 (en) * 2005-05-13 2009-07-23 Nevins Joseph R Gene Expression Signatures for Oncogenic Pathway Deregulation
WO2010094009A2 (en) * 2009-02-13 2010-08-19 Children's Hospital Medical Center Methods and compositions for the treatment of ras associated disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605799A (en) * 1990-07-12 1997-02-25 University Of Utah Research Foundation Somatic mutations in neurofibromatosis type 1 gene in human tumors
US5227292A (en) * 1990-07-12 1993-07-13 University Of Utah Neurofibromatosis type 1 gene

Also Published As

Publication number Publication date
WO2003060161A2 (en) 2003-07-24
IL147421A0 (en) 2002-08-14
WO2003060161A3 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
AU2003287735A1 (en) Non-invasive measurement of analytes
AU2003225839A1 (en) Modification of selectivity for sensing for nanostructure device arrays
AU2001289617A1 (en) Diagnosis of diseases associated with signal transduction
AU2002315200A1 (en) Production metering and well testing system background of the invention
AU2003220377A1 (en) Sensor for transcutaneous measurement of vascular access blood flow
AU2003300003A1 (en) Transducer for sensing body sounds
FI20031476A0 (en) Sensoring to measure signals received from the skin surface and method of making the sensor
AU2002330595A1 (en) Recalibration of downhole sensors
AU2003242988A1 (en) Process for the preparation of the anti-cancer drug imatinib and its analogues
AU2003281641A1 (en) Determining type of signal encoder
AU2003212822A1 (en) Methods for determining drug responsiveness
AU2003216116A1 (en) Deployment of downhole seismic sensors for microfracture detection
SI1475379T1 (en) Use of scopine ester derivatives for the synthesis of drugs
AU2002366989A1 (en) A method for assessing the potential responsiveness of a subject to anti-cancer drugs affecting the ras signal transduction pathway
AU2003258632A1 (en) Reconstruction of original signals from relative measurements
AU1647100A (en) Sensor for capacitive measurement of displacement
AU2003214560A1 (en) Test for measurement of therapeutic drug levels
AU2002364455A1 (en) Device for the capacitive measuring of a fill level
AU2002250613A1 (en) Microsensor for physiological pressure measurement
ITMI20032141A1 (en) PROCEDURE TO INFLUENCE THE MASS CONSTANCE OF
AU2003253850A1 (en) NON-INVASIVE MEASUREMENT OF pH
IS2441B (en) Use of pyridoindolone derivatives for the manufacture of anti-cancer drugs
EP1277840B8 (en) Drug sensitivity measuring method
IL166314A0 (en) A pharmaceutical composition containing a modulator of the signal transduction pathway via the protein kinase fyn
GB0206102D0 (en) Compact interferonmeter for measurement of angular displacement

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase